{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:12:03Z","timestamp":1788567123163,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471551"],"award-info":[{"award-number":["32471551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2025ZNSFSC1693"],"award-info":[{"award-number":["2025ZNSFSC1693"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3403304"],"award-info":[{"award-number":["2023YFC3403304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3403303"],"award-info":[{"award-number":["2023YFC3403303"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["ZYJC21003"],"award-info":[{"award-number":["ZYJC21003"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xcrm.2025.102409","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:55:36Z","timestamp":1760003736000},"page":"102409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity"],"prefix":"10.1016","volume":"6","author":[{"given":"Chen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102409_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102409_bib2","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1200\/JCO.2005.01.1031","article-title":"Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-M\u00fcnster Group 87","volume":"23","author":"Einsiedel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102409_bib3","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children\u2019s Oncology Group AALL0434 Methotrexate Randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102409_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02900","article-title":"CD5, an undercover regulator of TCR signaling","volume":"9","author":"Voisinne","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/323346a0","article-title":"Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1\/Leu-1","volume":"323","author":"Jones","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102409_bib6","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102409_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V82.2.343.343","article-title":"Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia","volume":"82","author":"Pui","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102409_bib8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.12042","article-title":"The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children\u2019s Oncology Group report","volume":"159","author":"Patel","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2025.102409_bib9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102409_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible transgene expression reduces fratricide and permits 4-1B costimulation of CAR T cells directed to T-cell malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102409_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102409_bib12","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","article-title":"The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains","volume":"29","author":"Dai","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2025.102409_bib13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.autrev.2008.11.007","article-title":"CD5: a safeguard against autoimmunity and a shield for cancer cells","volume":"8","author":"Dalloul","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.xcrm.2025.102409_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","article-title":"Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders","volume":"21","author":"Maskalenko","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2025.102409_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","article-title":"2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies","volume":"12","author":"Xu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102409_bib16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.it.2022.09.007","article-title":"Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers","volume":"43","author":"Pinto","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102409_bib18","article-title":"Natural killer cell engagers (NKCEs): a new frontier in cancer immunotherapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib19","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","article-title":"Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity","volume":"177","author":"Gauthier","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102409_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102409_bib21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2025.102409_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","article-title":"Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion","volume":"107","author":"Bryceson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102409_bib23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.xcrm.2025.102409_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1950264","article-title":"Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors","volume":"13","author":"Wingert","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.xcrm.2025.102409_bib25","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2021-152463","article-title":"AFM28, a Novel Bispecific Innate Cell Engager (ICE \u00ae), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"138","author":"G\u00f6tz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102409_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102409_bib27","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41375-021-01478-w","article-title":"A BCMA\/CD16A bispecific innate cell engager for the treatment of multiple myeloma","volume":"36","author":"Kakiuchi-Kiyota","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2025.102409_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.102409_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0167-5699(93)90166-I","article-title":"Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications","volume":"14","author":"van de Winkel","year":"1993","journal-title":"Immunol. Today"},{"key":"10.1016\/j.xcrm.2025.102409_bib30","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.3389\/fimmu.2018.03124","article-title":"Fc\u03b3RIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils","volume":"9","author":"Treffers","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib33","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood-2008-12-189266","article-title":"Safety and immunologic effects of IL-15 administration in nonhuman primates","volume":"114","author":"Berger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102409_bib34","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1016\/j.ymthe.2021.06.018","article-title":"Anti-NKG2C\/IL-15\/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia","volume":"29","author":"Chiu","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2025.102409_bib35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/bloodadvances.2018029371","article-title":"Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL","volume":"3","author":"Felices","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102409_bib36","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/bloodadvances.2018018176","article-title":"Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells","volume":"2","author":"Yun","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102409_bib37","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2025.102409_bib38","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.4143\/crt.2016.491","article-title":"Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity","volume":"49","author":"Schmohl","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102409_bib39","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3390\/cancers12092659","article-title":"NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo","volume":"12","author":"Vallera","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102409_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163994","article-title":"A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer","volume":"13","author":"Vallera","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102409_bib41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.xcrm.2025.102409_bib42","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","article-title":"Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia","volume":"77","author":"Campana","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102409_bib43","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1073\/pnas.79.10.3275","article-title":"Human neutrophil Fc gamma receptor distribution and structure","volume":"79","author":"Fleit","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102409_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1218082","article-title":"Engineering cytokines for cancer immunotherapy: a systematic review","volume":"14","author":"Fu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib45","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.177.9.6072","article-title":"Combined IL-15\/IL-15R\u03b1 immunotherapy maximizes IL-15 activity in vivo","volume":"177","author":"Stoklasek","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib46","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1078-0432.CCR-13-2302","article-title":"Natural killer cells: the secret weapon in dendritic cell vaccination strategies","volume":"20","author":"Van Elssen","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102409_bib47","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.92.19.8705","article-title":"Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15","volume":"92","author":"Johnston","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102409_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102409_bib49","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0092-8674(87)90086-9","article-title":"A C-terminal signal prevents secretion of luminal ER proteins","volume":"48","author":"Munro","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102409_bib50","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102409_bib51","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102409_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102409_bib53","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102409_bib54","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102409_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib56","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","article-title":"CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?","volume":"9","author":"Maciocia","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102409_bib57","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102409_bib58","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102409_bib59","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102409_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-024-01568-z","article-title":"Advances in CAR-T-cell therapy in T-cell malignancies","volume":"17","author":"Zheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102409_bib61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","article-title":"NK cell recognition","volume":"23","author":"Lanier","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib62","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib63","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/2326-6066.CIR-19-0837","article-title":"Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager","volume":"8","author":"Felices","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102409_bib64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/1044-5323(95)90006-3","article-title":"Function of human Fc\u03b3RIIA and Fc\u03b3RIIIB","volume":"7","author":"Unkeless","year":"1995","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib65","article-title":"Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy","volume":"13","author":"Nikkhoi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib66","first-page":"139","article-title":"Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells","volume":"77","author":"Giang","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102409_bib67","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30(+) malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102409_bib68","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1007\/s00262-021-03040-0","article-title":"Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL","volume":"70","author":"Reusing","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102409_bib69","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/mt.2016.88","article-title":"Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker","volume":"24","author":"Schmohl","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2025.102409_bib70","doi-asserted-by":"crossref","first-page":"73830","DOI":"10.18632\/oncotarget.12073","article-title":"Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker","volume":"7","author":"Schmohl","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102409_bib71","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib72","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","article-title":"Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib73","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102409_bib74","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1042\/ETLS20200331","article-title":"Affinity maturation: highlights in the application of in vitro strategies for the directed evolution of antibodies","volume":"5","author":"Chan","year":"2021","journal-title":"Emerg. Top. Life Sci."},{"key":"10.1016\/j.xcrm.2025.102409_bib75","article-title":"\u2018A landmark moment\u2019: scientists use AI to design antibodies from scratch","author":"Callaway","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102409_bib76","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102409_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867103","article-title":"Leukemia\u2019s Next Top Model? Syngeneic Models to Advance Adoptive Cellular Therapy","volume":"13","author":"Zoine","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102409_bib78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102409_bib79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.15252\/emmm.201606857","article-title":"Genetically engineered mouse models in oncology research and cancer medicine","volume":"9","author":"Kersten","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2025.102409_bib80","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40164-024-00522-6","article-title":"CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison","volume":"13","author":"Egli","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102409_bib81","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12951-024-02512-6","article-title":"BCMA\/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma","volume":"22","author":"Lu","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.xcrm.2025.102409_bib82","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-4939-8648-4_22","article-title":"Measuring antibody-antigen binding kinetics using surface plasmon resonance","volume":"1827","author":"Hearty","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.102409_bib83","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1189\/jlb.0311137","article-title":"Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation","volume":"90","author":"Marcenaro","year":"2011","journal-title":"J. Leukoc. Biol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:13:42Z","timestamp":1788563622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125004823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666379125004823"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102409","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102409"}}